Two of JDRF’s Industry Discovery and Development partners entered into global alliances with pharmaceutical companies to develop and commercialize treatments for early-stage type 1 diabetes. These collaborations have now moved “anti-CD3 antibodies” to the latest stage of clinical testing. In one partnership, between JDRF partner MacroGenics and Eli Lilly and Company, researchers have begun enrolling patients in a Phase III trial to test teplizumab, an antibody that has been effective in clinical trials at slowing disease progression in newly diagnosed patients. The second JDRF partner, Tolerx, formed an alliance with GlaxoSmithKline to develop otelixizumab, another anti-CD3 antibody that is in Phase III trials. If these collaborative partnerships successfully commercialize cures and treatments for diabetes, JDRF will also share in the financial results of that process, enabling the foundation to recoup its support of those projects and fund other research programs leading to a cure.